Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
George D. Yancopoulos

George D. Yancopoulos

President and Chief Scientific Officer, Regeneron Pharmaceuticals

Appears in 1 story

Notable Quotes

"With this approval, Dupixent once again demonstrates its value in advancing the treatment landscape for a chronic type 2 inflammatory disease with high unmet need. Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids with fewer patients having bone erosion in the sinuses." — on AFRS approval, February 2026

"We have programs that are first in class, the first drug that can really make a difference. Dupixent is a great example of such a drug that has changed an entire landscape for all these allergic diseases." — to shareholders, 2020

Stories

Dupixent becomes one of the most versatile drugs in pharmaceutical history

New Capabilities

Leading Regeneron's scientific strategy and Dupixent expansion

When the Food and Drug Administration (FDA) approved Dupixent for severe eczema in 2017, it was one drug for one disease. Nine years later, the same molecule has been approved for nine separate conditions, from asthma to a chronic fungal sinus infection that previously had no approved treatment at all. The latest approval, granted on February 24, 2026, covers allergic fungal rhinosinusitis (AFRS), a condition that traps patients in a cycle of repeated sinus surgeries. In a pivotal trial, Dupixent reduced the need for additional surgeries and steroid courses by 92%.

Updated Feb 24